Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
syha1813 + everolimus
- Development stage
- Unknown
- Lead developer
- CSPC Pharmaceutical Group
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
SYHA1813 + everolimus is an investigational **combination therapy** being evaluated in oncology clinical trials. SYHA1813 is a novel small molecule dual inhibitor targeting **Kinase insert domain receptor (VEGFR2)** and **Colony stimulating factor 1 receptor (CSF1R)**, aiming to disrupt both angiogenesis and macrophage-mediated immunosuppression, conferring potential anti-tumor activity and therapeutic benefit in high-grade gliomas and melanoma[7][1]. Everolimus is a well-established oral **mTOR (mechanistic target of rapamycin) inhibitor**, blocking a critical factor involved in cell growth, proliferation, and survival[4][6][8]. The combination is being studied in a phase Ib/II trial across multiple tumor types, with specific cohorts testing the safety and efficacy of SYHA1813 in combination with everolimus for various cancers[1].
- Other names
- syha1813syha-1813syha 1813everolimus
02
Targets
Mechanistic target of rapamycin complex 1
Beyond the preview
Go deeper on syha1813 + everolimus.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on syha1813 + everolimus.